Login to Your Account

Zerenex Phase III Data Wow; Keryx Hits 52-Week High

By Marie Powers
Staff Writer

Tuesday, January 29, 2013
Three weeks ago, Keryx Biopharmaceuticals Inc. CEO Ron Bentsur faced tough questions at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco about continuing delays in reporting long-term Phase III data on Zerenex (ferric citrate) for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription